长春高新：金赛药业将获得3款产品在中国大陆范围内独家代理权益

Core Insights - Changchun High-tech announced a collaboration with Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mite (HDM) allergens [1] - The agreement includes an initial payment of €32.7 million, with additional milestone payments totaling €40 million for regulatory approval and up to €105 million based on sales performance in China [1] - The global allergy immunotherapy market is projected to reach $3.2 billion by 2030, with a compound annual growth rate (CAGR) of 9.5%, highlighting significant growth potential in this sector [1] Company Summary - JinSai Pharmaceutical, a subsidiary of Changchun High-tech, will lead the collaboration and has secured exclusive rights to three products developed by ALK for the Chinese market [1] - The partnership aims to address the unmet clinical needs in China, where the number of patients receiving desensitization therapy is currently below 1 million, despite having the largest population of house dust mite allergy sufferers globally [1] Industry Summary - The allergy immunotherapy market in China is underdeveloped and lacks innovative products, presenting a substantial opportunity for growth [1] - The collaboration is expected to enhance the availability of effective treatments for a significant patient population suffering from dust mite allergies in China [1]